RxSight Future Growth
Future criteria checks 2/6
RxSight is forecast to grow earnings and revenue by 44.8% and 21.5% per annum respectively. EPS is expected to grow by 47.2% per annum. Return on equity is forecast to be -13.5% in 3 years.
Key information
44.8%
Earnings growth rate
47.2%
EPS growth rate
| Medical Equipment earnings growth | 17.1% |
| Revenue growth rate | 21.5% |
| Future return on equity | -13.5% |
| Analyst coverage | Good |
| Last updated | 02 Oct 2024 |
Recent future growth updates
Recent updates
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12RxSight: First And Only Customizable Intraocular Lens
Aug 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 233 | -11 | 10 | 15 | 6 |
| 12/31/2025 | 187 | -21 | -8 | 4 | 8 |
| 12/31/2024 | 140 | -31 | -26 | -1 | 8 |
| 6/30/2024 | 115 | -37 | -35 | -30 | N/A |
| 3/31/2024 | 101 | -44 | -39 | -33 | N/A |
| 12/31/2023 | 89 | -49 | -46 | -42 | N/A |
| 9/30/2023 | 77 | -55 | -51 | -47 | N/A |
| 6/30/2023 | 67 | -59 | -58 | -54 | N/A |
| 3/31/2023 | 58 | -62 | -64 | -62 | N/A |
| 12/31/2022 | 49 | -67 | -61 | -59 | N/A |
| 9/30/2022 | 41 | -67 | -56 | -54 | N/A |
| 6/30/2022 | 35 | -63 | -54 | -52 | N/A |
| 3/31/2022 | 28 | -59 | -51 | -49 | N/A |
| 12/31/2021 | 23 | -49 | -47 | -45 | N/A |
| 9/30/2021 | 19 | -15 | -46 | -44 | N/A |
| 6/30/2021 | 17 | 4 | -40 | -37 | N/A |
| 3/31/2021 | 15 | 17 | -35 | -33 | N/A |
| 12/31/2020 | 15 | 3 | -38 | -35 | N/A |
| 12/31/2019 | 2 | 26 | -45 | -41 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RXST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RXST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RXST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RXST's revenue (21.5% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: RXST's revenue (21.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RXST is forecast to be unprofitable in 3 years.